AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

HEALIUS LTD

1.335

-0.035-2.55%

Volume:2.98M

Turnover:4.01M

Market Cap:969.39M

PE:-42.04

High:1.385

Open:1.355

Low:1.330

Close:1.370

Loading ...

Overview Company News Filings

The next big thing: 10 industries and 17 stocks poised to break out in 2025

Marmota confirms high-value titanium discoveries at Muckanippie in South Australia

3 Undervalued ASX Small Caps With Recent Insider Buying In Australia

Simply Wall St.

Here are the top 10 ASX 200 shares today

Here are the top 10 ASX 200 shares today

2 ASX 200 shares to buy that this fund manager is bullish about

Hot Stock tip: This Aussie REIT will be ‘great short-term play’ as housing cools

The Market Herald

Undervalued Small Caps With Insider Action On ASX In November 2024

Simply Wall St.

This bombshell for ASX healthcare shares could hit 6 million Australians

Healius Could Return A$300 Million From Lumus Sale -- Market Talk

BUZZ-Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards

Detail Sought on Healius's Divestment Proceeds -- Market Talk

BUZZ-Jefferies notes Healius' positive outlook for its pathology business

Healius's Pathology Profitability Remains Challenged -- Market Talk

This ASX All Ords share is diving 18% as inflation pain draws blood

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HLS.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HLS.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HLS.AU\",,,,,undefined,":{"symbol":"HLS.AU","market":"AU","secType":"STK","nameCN":"HEALIUS LTD","latestPrice":1.335,"timestamp":1745302320000,"preClose":1.37,"halted":0,"volume":2979756,"delay":0,"nameEN":"HEALIUS LTD","floatShares":648466707,"shares":726134000,"eps":-0.031757,"marketStatus":"Not Yet Opened","change":-0.035,"latestTime":"04-22 16:12:00 AEST","open":1.355,"high":1.385,"low":1.33,"amount":4008265,"amplitude":0.040146,"askPrice":1.35,"askSize":20000,"bidPrice":1.335,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-0.031757,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.37,"dividendRate":0.044944,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":1.788835742290083,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HLS.AU\",,,,,undefined,":{"symbol":"HLS.AU","floatShares":648466707,"roa":"1.34%","roe":"-3.08%","lyrEps":-0.97884,"volumeRatio":1.788835742290083,"shares":726134000,"dividePrice":0.06,"high":1.385,"amplitude":0.040146,"preClose":1.37,"low":1.33,"week52Low":1.08,"pbRate":"0.94","psRate":"0.54","week52High":1.86,"institutionHeld":0,"latestPrice":1.335,"eps":-0.031757,"divideRate":0.044944,"volume":2979756,"delay":0,"ttmEps":-0.031757,"open":1.355,"prevYearClose":1.37,"prevWeekClose":1.37,"prevMonthClose":1.395,"prevQuarterClose":1.395,"fiveDayClose":1.4,"twentyDayClose":1.335,"sixtyDayClose":1.415},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HLS.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2502026684","title":"The next big thing: 10 industries and 17 stocks poised to break out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502026684","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502026684?lang=en_us&edition=fundamental","pubTime":"2025-01-10 04:00","pubTimestamp":1736452814,"startTime":"0","endTime":"0","summary":"Move over big tech, there are more opportunities in town.After starting 2024 with earnings downgrades for a range of sectors and a slowdown in consumer spending, it was a bumper year for a number of sectors. Consumer discretionary was one surprise winner, with well-positioned brands like JB Hi-Fi and Nick Scali taking charge. Australian banks facing into a tougher environment continued to outperform, as did the financial sector on the whole, with insurers taking advantage of higher premiums. Biotech also started to surge, as falling rates outside of Australia and a number of successful clinical trials bolstered the sector.Of course, the big tech companies continued to dominate and push markets to record highs - it's hard to ignore the extraordinary growth in the likes of Nvidia for example, but it's worth noting the pace of the growth seems to be moderating somewhat.With valuations at a premium in the tech sector, there are a range of other areas where fund managers are hunting for big","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-next-big-thing-10-industries-and-17-stocks-poised-to-break-out-in-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4591","BK7503","BK7016","DSE.AU","AS","BK4156","BK4566","BK7501","HLS.AU","CCJ","BK4585","BK7123","BK7124","BK7110","ASB.AU","BK7115","BK7083","BK7067","BK4533","CSC.AU","BK4504","BK7509","BK7160","LU2294711713.HKD","IE0008368304.USD","SHL.AU","BOE.AU","LU2249611893.SGD","BK7508","LU2506951792.HKD","GTK.AU","LU2357125470.USD","XJO.AU","AFG.AU","LU0823414551.USD","LU0823414478.USD","XKO.AU","BK4588","ODFL","OPT.AU","ACL.AU","XAO.AU","BK4232","BK4022","BK4202"],"gpt_icon":0},{"id":"2501135742","title":"Marmota confirms high-value titanium discoveries at Muckanippie in South Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2501135742","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501135742?lang=en_us&edition=fundamental","pubTime":"2025-01-07 09:03","pubTimestamp":1736211809,"startTime":"0","endTime":"0","summary":"Marmota  has further confirmed the potential of its recent Muckanippie heavy minerals discovery in South Australia with the identification of a regional scale palaeochannel of high-value titanium.New studies suggest the palaeochannel crosses Marmota’s discovery of exceptional thick rich titanium mineralisation at Muckanippie and Petratherm’s  nearby discovery of thick rich titanium mineralisation.Marmota’s management says the confirmation of the palaeochannel also expands the prospective areas for channel/fluvial hosted titanium mineralisation on its Muckanippie tenement EL 6166, and its adjacent tenements EL 6679 and EL 6005 permits.Marmota is estimated to hold approximately 28km in length of the highly prospective titanium-bearing palaeochannel on its tenements, with around 10km lying within the company’s tenements to the west, and a further 18km within tenements to the east.Precedence Research has estimated that the global titanium market was valued at $45.8 billion in 2024 and is a","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Marmota-ASX-MEU-titanium-discoveries-Muckanippie-South-Australia.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Marmota-ASX-MEU-titanium-discoveries-Muckanippie-South-Australia.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/marmota-high-value-titanium-discoveries-muckanippie-south-australia/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7095","XRF.AU","XAO.AU","PTR.AU","XJO.AU","BK7088","BK7124","BK7501","BK7509","MEU.AU","BK7083","XKO.AU","HLS.AU"],"gpt_icon":0},{"id":"2495851514","title":"3 Undervalued ASX Small Caps With Recent Insider Buying In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2495851514","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495851514?lang=en_us&edition=fundamental","pubTime":"2024-12-30 17:07","pubTimestamp":1735549640,"startTime":"0","endTime":"0","summary":"As the Australian market closed slightly down on the penultimate trading day of 2024, with only Energy and Healthcare sectors showing positive movement, broader sentiment remains cautious amid slow trade and profit-taking. In this environment, identifying promising small-cap stocks can be challenging but rewarding, especially when considering factors like recent insider buying which may signal confidence in a company's future prospects.Click here to see the full list of 25 stocks from our Undervalued ASX Small Caps With Insider Buying screener.Overview: Deterra Royalties is a company focused on managing royalty arrangements, primarily deriving its income from these agreements, with a market cap of A$2.33 billion.Overview: Healius is a healthcare company that operates in the pathology and imaging sectors, with a market cap of A$2.50 billion.Operations: Healius generates revenue primarily from its Pathology and Imaging segments, with Pathology contributing significantly more to the total","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-undervalued-asx-small-caps-090720867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7016","XKO.AU","BK7124","HLS.AU","DRR.AU","BK7501","BK7503","XJO.AU","BK7129","IFM.AU","XAO.AU","BK7509"],"gpt_icon":0},{"id":"2491520630","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2491520630","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491520630?lang=en_us&edition=fundamental","pubTime":"2024-12-16 14:08","pubTimestamp":1734329312,"startTime":"0","endTime":"0","summary":"It was a fairly nasty start to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Monday. After a rough week last week, investors clearly didn't get their mojo back over th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/16/here-are-the-top-10-asx-200-shares-today-553/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SGR.AU","WGX.AU","BK7104","BK7034","SDR.AU","BK7051","XJO.AU","TCL.AU","BOQ.AU","TLX.AU","HLS.AU","BK7139","BK7509","BK7078","BK7124","BK7007","BK7016","IAG.AU","BK7090","BK7501","AOV.AU","FPH.AU","BK7506","BK7067"],"gpt_icon":0},{"id":"2490713014","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2490713014","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490713014?lang=en_us&edition=fundamental","pubTime":"2024-12-09 14:01","pubTimestamp":1733724103,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) had a slow start to the trading week this Monday. By market close today, the ASX 200 had risen by an anaemic 0.025% after spending most of the day in negative territor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/09/here-are-the-top-10-asx-200-shares-today-548/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7035","BK7119","BRG.AU","BK7073","BK7124","CDA.AU","LTM.AU","BK7509","BK7501","BK7104","BK7155","GMG.AU","BK7036","XJO.AU","BK7510","BK7102","AIA.AU","EVT.AU","BK7503","BK7007","BK7099","AD8.AU","HLS.AU","CMM.AU","RMD.AU","BK7084"],"gpt_icon":1},{"id":"2489166484","title":"2 ASX 200 shares to buy that this fund manager is bullish about","url":"https://stock-news.laohu8.com/highlight/detail?id=2489166484","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489166484?lang=en_us&edition=fundamental","pubTime":"2024-12-06 05:30","pubTimestamp":1733434200,"startTime":"0","endTime":"0","summary":"The fund managers from WAM Leaders Ltd (ASX: WLE) have revealed two S&P/ASX 200 Index (ASX: XJO) shares that they're excited about. WAM Leaders — a listed investment company (LIC) under Wilson Asset M","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/06/2-asx-200-shares-to-buy-that-this-fund-manager-is-bullish-about/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["ANZ.AU","WBC.AU","AGM.AU","BK7501","BK4195","HLS.AU","BK7145","AGM","SHL.AU","BK7511","LIC.AU","BK4229","XJO.AU","QBE.AU","BK7034","WLE.AU","CBA.AU","BK7135","BK7509","BK7124"],"gpt_icon":0},{"id":"2488952093","title":"Hot Stock tip: This Aussie REIT will be ‘great short-term play’ as housing cools","url":"https://stock-news.laohu8.com/highlight/detail?id=2488952093","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488952093?lang=en_us&edition=fundamental","pubTime":"2024-12-03 12:08","pubTimestamp":1733198880,"startTime":"0","endTime":"0","summary":"Wealth Within senior analystFil Tortevski, this week joined by analyst Pedro Banales, has picked real estate investment trust Charter Hall Long  as his HotCopper Hot Stock tip today as it approaches a “very important level.”This REIT is of particular interest, Mr Tortevski explained, because the property market is now very clearly “cooling off… even if people want to say it’s not happening.”That applies mostly to Sydney and Melbourne, the Wealth Within senior analyst added.“We’re closing near the high of that November bar following two really nice periods of expansion,” Mr Tortevski continued. “You’d be pretty hard pressed to find a very clean scenario where there’s clear highs and lows recently.”Harvey Norman  is Wealth Within’s caution stock for the week, though Mr Tortevski made clear it’s “not a bearish caution by any means… this one is a bullish caution.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/hot-stock-tip-this-aussie-reit-will-be-great-short-term-play-as-housing-cools-2024-12-03/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7509","HLS.AU","BK7501","BK7124","BK7153","BK7087","HVN.AU","CLW.AU","BK7041","REIT"],"gpt_icon":0},{"id":"2486668360","title":"Undervalued Small Caps With Insider Action On ASX In November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486668360","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486668360?lang=en_us&edition=fundamental","pubTime":"2024-11-28 17:01","pubTimestamp":1732784512,"startTime":"0","endTime":"0","summary":"In recent weeks, the Australian market has demonstrated resilience, with the ASX200 reaching new highs despite mixed performances across various sectors. While Health Care and Financials have shown strength, Energy and Industrials have lagged behind, highlighting a diverse landscape for investors to navigate. In this context, identifying small-cap stocks with potential insider action can offer unique opportunities for those seeking growth in an evolving market environment.Top 10 Undervalued Small Caps With Insider Buying In Australia. Click here to see the full list of 28 stocks from our Undervalued ASX Small Caps With Insider Buying screener.Overview: Infomedia is a company that specializes in providing software solutions and data analytics for the automotive industry, with a market capitalization of A$0.45 billion.Operations: The revenue model primarily revolves around publishing periodicals, with recent revenues reaching A$140.83 million. Operating expenses are significant,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sdPtv1rH.MgIH3Zp08EpWw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fa1ce98932751d6e1bf9cbe1db62e574","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sdPtv1rH.MgIH3Zp08EpWw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fa1ce98932751d6e1bf9cbe1db62e574"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/undervalued-small-caps-insider-action-090152804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7016","BK7501","BK7509","XAO.AU","HLS.AU","BK7503","IFM.AU","BK7121","BK7124","QAL.AU","BK7062","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2485403064","title":"This bombshell for ASX healthcare shares could hit 6 million Australians","url":"https://stock-news.laohu8.com/highlight/detail?id=2485403064","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485403064?lang=en_us&edition=fundamental","pubTime":"2024-11-22 10:55","pubTimestamp":1732244127,"startTime":"0","endTime":"0","summary":"ASX healthcare shares could feel the aftershocks of Healthscope's decision if they cause widespread impact for Aussie savers.  The hospital operator revealed it would sever ties with Bupa in February 2025 and with AHSA in March. The latter represents 22 smaller not-for-profit funds.  At the core of the dispute is Healthscope's proposed hospital facility fee, designed to cover the rising costs of private healthcare. Bupa and AHSA opposed the fee, threatening legal action to block it. Healthscope CEO Greg Horan defended the move, stating that the private hospital sector in Australia is experiencing a \"viability crisis\".   \"In an environment of rising costs and private hospital closures, it is unacceptable for insurers to fail their core purpose – funding the care of their members\", he said. Horan also highlighted that 70 private hospitals have closed in the past five years, according to The Sydney Morning Herald. This has been seen in the returns of some ASX healthcare shares. What does ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/22/this-bombshell-for-asx-healthcare-shares-could-hit-6-million-australians/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7509","XJO.AU","IE00B775SV38.USD","BK7113","BK4585","XKO.AU","RHC.AU","IE00B3S45H60.SGD","BK4135","BK7124","BK7501","BK4588","SHL.AU","XAO.AU","HLS.AU","BN"],"gpt_icon":0},{"id":"2484075609","title":"Healius Could Return A$300 Million From Lumus Sale -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2484075609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484075609?lang=en_us&edition=fundamental","pubTime":"2024-11-20 06:52","pubTimestamp":1732056720,"startTime":"0","endTime":"0","summary":"2251 GMT - Healius could return some A$300 million to its shareholders from selling its imaging business Lumus, reckons Citi. Healius in September said it would sell Lumus to Affinity Equity Partners for A$965 million, but didn't specify how much of the proceeds would be returned to shareholders. Analyst Mathieu Chevrier thinks it could involve Healius declaring a special dividend of A$0.40/share. \"We upgrade to Neutral on recent share price decline, sale of Lumus which will make Healius debt-free, and a pathology cost base now likely more reflective of true business-as-usual costs,\" Citi says. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","HLS.AU","BK7124","BK7501"],"gpt_icon":0},{"id":"2484970859","title":"BUZZ-Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards","url":"https://stock-news.laohu8.com/highlight/detail?id=2484970859","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484970859?lang=en_us&edition=fundamental","pubTime":"2024-11-20 04:14","pubTimestamp":1732047263,"startTime":"0","endTime":"0","summary":"BUZZ-Citi ups Australia's Healius to 'neutral' rating, sees special dividend on the cards** Citi upgrades Healius' HLS.AX rating to \"neutral\" from \"sell\" on recent share price decline, the sale of co's unit Lumus Imaging and cost base of its pathology segment reflecting its true business as usual costs** Brokerage trims price target for co to A$1.05 from A$1.5 to reflect Lumus sale in its forecasts** Citi forecasts HLS to distribute special dividend of 40 Australian cents/share from sale of Lumus** The Aussie healthcare firm on Friday shared positive outlook for its pathology business, foreacsting strong growth in 2H** HLS down ~19.9% YTD as of last close, underperforming against a 3.4% gain on the ASX Health Care index .AXHJ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nL4N3MQ1ME:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HLS.AU"],"gpt_icon":0},{"id":"2484166301","title":"Detail Sought on Healius's Divestment Proceeds -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2484166301","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484166301?lang=en_us&edition=fundamental","pubTime":"2024-11-18 08:29","pubTimestamp":1731889740,"startTime":"0","endTime":"0","summary":"0029 GMT - Healius's divestment of its Lumus Imaging unit makes sense but the Australian pathology provider needs to give further detail on where it will deploy the proceeds, Macquarie analysts say. They see the divestment improving the Australia-listed company's balance sheet position, but want to know how it will deploy surplus proceeds into productivity and profitability initiatives. The analysts tell clients in a note that they expect net proceeds of about A$800 million and for Healius to repay its existing debt facilities, thus reducing net interest costs. Macquarie cuts its target price 16% to A$1.35 and keeps a neutral rating on the stock, which is down 4.7% at A$1.2725. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","BK7124","HLS.AU","BK7501"],"gpt_icon":0},{"id":"2484571056","title":"BUZZ-Jefferies notes Healius' positive outlook for its pathology business","url":"https://stock-news.laohu8.com/highlight/detail?id=2484571056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484571056?lang=en_us&edition=fundamental","pubTime":"2024-11-18 07:06","pubTimestamp":1731884795,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies notes Healius' positive outlook for its pathology business** Jefferies says Healius HLS.AX sees strong second half growth for its pathology business    ** Analysts at Jefferies forecast for HLS' pathology business an EBIT margin of 1.1% in 1HFY25 and 4.6% 2HFY25** The Aussie healthcare firm said on Friday it sees 1H25 EBIT for its pathology business broadly in line with 1H24, while anticipating an increase in pathology earnings in 2HFY25** Company's 1HFY24 EBIT was A$6 million  while Jefferies estimate was A$7 million** Brokerage says HLS's elevated cost base continues to be an issue** Brokerage cuts price target for co to A$1.45 from A$1.75; retains \"hold\" rating** HLS down 18.4% so far this year as of last close, underperforming against a 3.7% gain on the ASX Health Care index .AXHJ  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nL4N3MO05P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7509","BK7124","HLS.AU","BK7501"],"gpt_icon":0},{"id":"2484652594","title":"Healius's Pathology Profitability Remains Challenged -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2484652594","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484652594?lang=en_us&edition=fundamental","pubTime":"2024-11-18 06:27","pubTimestamp":1731882420,"startTime":"0","endTime":"0","summary":"2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. \"Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability,\" says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","BK7509","HLS.AU","BK7501"],"gpt_icon":0},{"id":"2483391909","title":"This ASX All Ords share is diving 18% as inflation pain draws blood","url":"https://stock-news.laohu8.com/highlight/detail?id=2483391909","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483391909?lang=en_us&edition=fundamental","pubTime":"2024-11-15 11:21","pubTimestamp":1731640896,"startTime":"0","endTime":"0","summary":"It's been a rough few years for Healius shares investors.  In December 2021, during the COVID-19 pandemic, Healius shares were trading for just under $5. Since then, shares in the ASX All Ords healthcare stock have lost 73% of their value and are down 22% over the past 12 months. Anderson, who became CEO in March following Maxine Jaquet's resignation, said Healius had listened to shareholders.  He said management had spent the past six months reshaping the company's strategy and capital structure \"to create further shareholder value\".  He said Healius had \"made a good deal of headway on initiatives that we believe will make a real difference to our business\" in FY24. This included refinancing bank debt and undertaking a review of assets, which resulted in the proposed sale of Lumus Imaging in September for $965 million. He added","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/15/this-asx-all-ords-share-is-diving-18-as-inflation-pain-draws-blood/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK7509","HLS.AU","BK4195","AGM","BK4229","XAO.AU","BK7124","AGM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HLS.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-20","symbol":"HLS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740006000000,"name":null,"time":"","dateTimestamp":1739970000000,"actualEps":null},{"date":"2024-08-21","symbol":"HLS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724198400000,"name":null,"time":"","dateTimestamp":1724162400000,"actualEps":null},{"date":"2024-02-27","symbol":"HLS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708988400000,"name":null,"time":"","dateTimestamp":1708952400000,"actualEps":null},{"date":"2023-08-30","symbol":"HLS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693353600000,"name":null,"time":"","dateTimestamp":1693317600000,"actualEps":null},{"date":"2023-02-27","symbol":"HLS.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1677452400000,"name":null,"time":"","dateTimestamp":1677416400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HLS.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2021-03-25","recordDate":"2021-03-26","paymentDate":"2021-04-15","value":0.065,"currency":"AUD"},{"executeDate":"2021-09-13","recordDate":"2021-09-14","paymentDate":"2021-10-08","value":0.0675,"currency":"AUD"},{"executeDate":"2022-03-24","recordDate":"2022-03-25","paymentDate":"2022-04-05","value":0.1,"currency":"AUD"},{"executeDate":"2022-09-07","recordDate":"2022-09-08","paymentDate":"2022-09-21","value":0.06,"currency":"AUD"}]}}